Ginkgo Bioworks Holdings, Inc. reported a significant decline in its financial performance for the fiscal year ending December 31, 2025, with total revenue of $170.2 million, down from $227.0 million in 2024. The decrease was primarily driven by a reduction in both cell engineering and biosecurity revenues, which fell by $41.2 million and $15.7 million, respectively. The company attributed the decline in cell engineering revenue to the recognition of $45.4 million in non-cash revenue from a terminated contract in 2024, while biosecurity revenue was impacted by lower government contracts. Ginkgo's net loss for the year was $312.8 million, an improvement from a loss of $547.0 million in the previous year, reflecting a reduction in operating expenses due to restructuring efforts.
In terms of operational changes, Ginkgo has undergone a significant restructuring plan initiated in 2024, which included a workforce reduction of over 50% and the consolidation of facilities. This restructuring is expected to yield long-term savings, although it has resulted in immediate costs, including $11.4 million in restructuring charges for 2025. The company has also shifted its focus towards enhancing its cell engineering tools offerings, which began in 2024, and has removed downstream value share from certain program types to create more predictable revenue streams.
Ginkgo's customer base remains concentrated, with one customer accounting for 15% of cell engineering revenue and another for 12% of biosecurity revenue in 2025. The company noted that the loss of any significant customer could adversely affect its financial performance and market reputation. As of December 31, 2025, Ginkgo had 485 employees, a reduction from previous years, and is focused on attracting and retaining talent to support its ongoing projects and future growth.
Looking ahead, Ginkgo Bioworks expressed cautious optimism about its future, emphasizing its commitment to developing its platform and expanding its service offerings. The company has approximately $167.2 million in cash and cash equivalents, which it believes will be sufficient to fund operations for at least the next 12 months. However, it acknowledged the need for additional capital to support its growth initiatives and the potential for future losses as it continues to invest in research and development. The company is also navigating a complex regulatory environment, particularly in the biosecurity sector, which could impact its ability to scale operations and secure new contracts.
About Ginkgo Bioworks Holdings, Inc.
Ginkgo BioWorks is a biotechnology company specializing in cell engineering and biosecurity. It provides R&D services, tools, and platforms to develop biologics, gene therapies, vaccines, and agricultural solutions. Its core value lies in making biology easier to engineer through automation, AI, and data assets, serving industries like pharmaceuticals, agriculture, industrial biotech, and government, with a focus on innovation, scalability, and biosecurity.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.